Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Tumor-Agnostic 2Thoracic 2NET 2Endocrine 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 4Sarcoma, Ewing 3Neoplasms 3Stomach Neoplasms 1Neuroendocrine Tumors 1Mesothelioma 1Leiomyosarcoma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × PM 01183 × Sarcoma × Clear all
NCT06088290 2026-05-15

SaLuDo

PharmaMar

Phase 3 Active not recruiting
455 enrolled
Sarcoma

Leiomyosarcoma, Neoplasms

NCT05918640 2026-03-31

LiFFT

Children's Hospital of Philadelphia

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Neoplasms, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡